Review | Published:

New insights on the role of the endocannabinoid system in the regulation of energy balance

International Journal of Obesity volume 40, pages 210219 (2016) | Download Citation

Abstract

Within the past 15 years, the endocannabinoid system (ECS) has emerged as a lipid signaling system critically involved in the regulation of energy balance, as it exerts a regulatory control on every aspect related to the search, the intake, the metabolism and the storage of calories. An overactive endocannabinoid cannabinoid type 1 (CB1) receptor signaling promotes the development of obesity, insulin resistance and dyslipidemia, representing a valuable pharmacotherapeutic target for obesity and metabolic disorders. However, because of the psychiatric side effects, the first generation of brain-penetrant CB1 receptor blockers developed as antiobesity treatment were removed from the European market in late 2008. Since then, recent studies have identified new mechanisms of action of the ECS in energy balance and metabolism, as well as novel ways of targeting the system that may be efficacious for the treatment of obesity and metabolic disorders. These aspects will be especially highlighted in this review.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , . Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol Med 2011; 17: 518–526.

  2. 2.

    , , . The role of the endocannabinoid system in the neuroendocrine regulation of energy balance. J Psychopharmacol 2012; 26: 114–124.

  3. 3.

    , . The thrifty lipids: endocannabinoids and the neural control of energy conservation. Trends Neurosci 2012; 35: 403–411.

  4. 4.

    , . The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab 2013; 17: 475–490.

  5. 5.

    . The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 2009; 60: 77–84.

  6. 6.

    , . Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 2008; 14: 923–930.

  7. 7.

    , , , , , et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 2010; 62: 588–631.

  8. 8.

    , , , , . The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27: 73–100.

  9. 9.

    , . Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Expert Opin Investig Drugs 2012; 21: 1309–1322.

  10. 10.

    , . Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001; 410: 588–592.

  11. 11.

    , , , , , . Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 1998; 63: PL113–PL117.

  12. 12.

    , , , . SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 1998; 9: 179–181.

  13. 13.

    , . Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 1999; 143: 315–317.

  14. 14.

    , , , . Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity. J Endocrinol Invest 2003; 26: 1041–1044.

  15. 15.

    , , . Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121–2134.

  16. 16.

    , . CB1 antagonists for obesity—what lessons have we learned from rimonabant? Nat Rev Endocrinol 2009; 5: 633–638.

  17. 17.

    , , , , . Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295: 761–775.

  18. 18.

    , , , , . Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389–1397.

  19. 19.

    , , , , , et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423–431.

  20. 20.

    , , , , . CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004; 28: 640–648.

  21. 21.

    , , , , . Central nervous system control of food intake and body weight. Nature 2006; 443: 289–295.

  22. 22.

    , , , . The tempted brain eats: pleasure and desire circuits in obesity and eating disorders. Brain Res 2010; 1350: 43–64.

  23. 23.

    , . Hindbrain neurons as an essential hub in the neuroanatomically distributed control of energy balance. Cell Metab 2012; 16: 296–309.

  24. 24.

    , . Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 2001; 134: 1151–1154.

  25. 25.

    , , , . Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002; 136: 550–557.

  26. 26.

    , , . Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward. Neuropsychopharmacology 2007; 32: 2267–2278.

  27. 27.

    , , , , . Cannabinoid facilitation of behavioral and biochemical hedonic taste responses. Neuropharmacology 2012; 63: 161–168.

  28. 28.

    , , , , , . The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food. Neurosci Lett 2007; 419: 231–235.

  29. 29.

    , , . Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 2006; 29: 225–232.

  30. 30.

    , . Activating parabrachial cannabinoid CB1 receptors selectively stimulates feeding of palatable foods in rats. J Neurosci 2008; 28: 9702–9709.

  31. 31.

    , , , , , et al. The endocannabinoid system controls food intake via olfactory processes. Nat Neurosci 2014; 17: 407–415.

  32. 32.

    , , , , , et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822–825.

  33. 33.

    , , , , . Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron 2005; 48: 1055–1066.

  34. 34.

    , , , , , et al. Hypothalamic CB1 cannabinoid receptors regulate energy balance in mice. Endocrinology 2012; 153: 4136–4143.

  35. 35.

    , , , , , et al. CB1 cannabinoid receptor in SF1-expressing neurons of the ventromedial hypothalamus determines metabolic responses to diet and leptin. Mol Metab 2014; 3: 705–716.

  36. 36.

    , , , , , et al. Obesity-driven synaptic remodeling affects endocannabinoid control of orexinergic neurons. Proc Natl Acad Sci USA 2013; 110: E2229–E2238.

  37. 37.

    , , , . Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci 2003; 23: 4850–4857.

  38. 38.

    , , , , , et al. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J Neurosci 2006; 26: 6643–6650.

  39. 39.

    , , , , . Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis. Diabetes 2011; 60: 1055–1062.

  40. 40.

    , , , . The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol 2004; 143: 520–523.

  41. 41.

    , , . AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 2012; 13: 251–262.

  42. 42.

    , , , , , et al. The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system. PLoS One 2008; 3: e1797.

  43. 43.

    , , , . Cannabinoids enhance gastric X/A-like cells activity. Folia Histochem Cytobiol 2008; 46: 219–224.

  44. 44.

    , , , , , et al. Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2-arachidonoyl-glycerol in healthy humans: a pilot study. J Clin Endocrinol Metab 2012; 97: E917–E924.

  45. 45.

    , , , , , et al. Bimodal control of stimulated food intake by the endocannabinoid system. Nat Neurosci 2010; 13: 281–283.

  46. 46.

    , , , , , et al. Cannabinoid type 1 (CB1) receptors on Sim1-expressing neurons regulate energy expenditure in male mice. Endocrinology 2015; 156: 411–418.

  47. 47.

    , , , , , et al. Activation of the sympathetic nervous system mediates hypophagic and anxiety-like effects of CB(1) receptor blockade. Proc Natl Acad Sci USA 2013; 110: 4786–4791.

  48. 48.

    . Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol 2008; 160: 1–24.

  49. 49.

    , , , , , et al. Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Nat Neurosci 2011; 14: 345–350.

  50. 50.

    , , , , , et al. Mitochondrial CB(1) receptors regulate neuronal energy metabolism. Nat Neurosci 2012; 15: 558–564.

  51. 51.

    , , , , , et al. Cannabinoid control of brain bioenergetics: exploring the subcellular localization of the CB1 receptor. Mol Metab 2014; 3: 495–504.

  52. 52.

    , , , , , et al. Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 2012; 148: 1039–1050.

  53. 53.

    , , , , , et al. Astroglial CB1 cannabinoid receptors regulate leptin signaling in mouse brain astrocytes. Mol Metab 2013; 2: 393–404.

  54. 54.

    , , , . Emerging role of glial cells in the control of body weight. Mol Metab 2012; 1: 37–46.

  55. 55.

    , , , , , et al. Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice. Diabetologia 2011; 54: 3121–3131.

  56. 56.

    , , , , , et al. CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab 2010; 11: 273–285.

  57. 57.

    , , . The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure. Obesity (Silver Spring) 2009; 17: 254–261.

  58. 58.

    , , , , , et al. The PVH as a site of CB1-mediated stimulation of thermogenesis by MC4R agonism in male rats. Endocrinology 2014; 155: 3448–3458.

  59. 59.

    , , , , , et al. 2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism. Cell Metab 2012; 15: 299–310.

  60. 60.

    , , , , , et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22: 9612–9617.

  61. 61.

    , , , , , et al. Endocannabinoids selectively enhance sweet taste. Proc Natl Acad Sci USA 2010; 107: 935–939.

  62. 62.

    , , , , , et al. Endocannabinoids measurement in human saliva as potential biomarker of obesity. PLoS One 2012; 7: e42399.

  63. 63.

    , , , , . Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci USA 2011; 108: 12904–12908.

  64. 64.

    , , , . Endocannabinoid signaling in the gut mediates preference for dietary unsaturated fats. FASEB J 2013; 27: 2513–2520.

  65. 65.

    . Is fat taste ready for primetime? Physiol Behav 2014; 136: 145–154.

  66. 66.

    . Metabolism in 2013: the gut microbiota manages host metabolism. Nat Rev Endocrinol 2014; 10: 74–76.

  67. 67.

    , , , , , et al. The endocannabinoid system links gut microbiota to adipogenesis. Mol Syst Biol 2010; 6: 392.

  68. 68.

    , , , , , et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013; 110: 9066–9071.

  69. 69.

    , , , , , et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63: 908–914.

  70. 70.

    , , , , , . Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol 2005; 517: 174–181.

  71. 71.

    , , , , , et al. Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose tissue, muscle, and liver: the role of eNOS, p38 MAPK, and AMPK pathways. Diabetes 2010; 59: 2826–2836.

  72. 72.

    , , , , , et al. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes 2008; 57: 2028–2036.

  73. 73.

    , , , , , et al. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes. Diabetes Obes Metab 2010; 12: 158–166.

  74. 74.

    , , , , , et al. Peripheral cannabinoid 1 receptor blockade activates brown adipose tissue and diminishes dyslipidemia and obesity. FASEB J 2014; 28: 5361–5375.

  75. 75.

    , , , , , et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006; 91: 3171–3180.

  76. 76.

    , , , , , . The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. Diabetes 2008; 57: 1262–1268.

  77. 77.

    , , , , , . Effect of the cannabinoid receptor-1 antagonist rimonabant on lipolysis in rats. Eur J Pharmacol 2010; 646: 38–45.

  78. 78.

    , , , , , . Adipocye-specific CB1 conditional knock-out mice: new insights in the study of obesity and metabolic syndrome. Paper presented at the 20th Annual Symposium of the International Cannabinoid Society 23–27 July 2010 Lund, Sweden International Cannabinoid Research Society: Research Triangle Park, NC, USA, 2010.

  79. 79.

    , , , , , et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298–1305.

  80. 80.

    , , , , , et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008; 118: 3160–3169.

  81. 81.

    , , , , , et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010; 120: 2953–2966.

  82. 82.

    , , , , , et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab 2012; 16: 167–179.

  83. 83.

    , , , , , et al. Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology 2012; 142: 1218–1228 e1211.

  84. 84.

    , , . Cannabinoid signaling and liver therapeutics. J Hepatol 2013; 59: 891–896.

  85. 85.

    , , . Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas. Pharmacol Ther 2011; 129: 307–320.

  86. 86.

    , , , , , et al. CB1 cannabinoid receptors couple to focal adhesion kinase to control insulin release. J Biol Chem 2013; 288: 32685–32699.

  87. 87.

    , , , , , et al. Cannabinoids inhibit insulin receptor signaling in pancreatic beta-cells. Diabetes 2011; 60: 1198–1209.

  88. 88.

    , , , , , et al. Cannabinoids induce pancreatic beta-cell death by directly inhibiting insulin receptor activation. Sci Signal 2012; 5: ra23.

  89. 89.

    , , , , , et al. Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med 2013; 19: 1132–1140.

  90. 90.

    , , , , , et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838–2843.

  91. 91.

    , , , , , et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55: 3053–3060.

  92. 92.

    , , , , , et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007; 31: 692–699.

  93. 93.

    , , , , , et al. Simultaneous postprandial deregulation of the orexigenic endocannabinoid anandamide and the anorexigenic peptide YY in obesity. Int J Obes (Lond) 2012; 36: 880–885.

  94. 94.

    , , , , , et al. Estimation of reference intervals of five endocannabinoids and endocannabinoid related compounds in human plasma by two dimensional-LC/MS/MS. J Lipid Res 2011; 53: 481–493.

  95. 95.

    , , , , , et al. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. Br J Pharmacol 2007; 152: 676–690.

  96. 96.

    , , , , , et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994; 350: 240–244.

  97. 97.

    . CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev 2007; 23: 507–517.

  98. 98.

    , , , . The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice. J Neurosci 2010; 30: 7369–7376.

  99. 99.

    , , , , , et al Antagonists of CB1 receptor. Patent Publication No. WO/2012/160006. International Application No.: PCT/EP2012/059310 2012.

  100. 100.

    , , , , , et al. Central functional response to the novel peptide cannabinoid, hemopressin. Neuropharmacology 2013; 71: 27–36.

  101. 101.

    , , , , , et al. Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors. J Biol Chem 2012; 287: 36944–36967.

  102. 102.

    , , , , , et al. Pregnenolone can protect the brain from cannabis intoxication. Science 2014; 343: 94–98.

  103. 103.

    , , , , , et al. A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects. Br J Pharmacol 2013; 169: 784–793.

  104. 104.

    , , , , , et al. Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr 2009; 139: 1495–1501.

  105. 105.

    , , , , , et al. Sheep cheese naturally enriched in alpha-linolenic, conjugated linoleic and vaccenic acids improves the lipid profile and reduces anandamide in the plasma of hypercholesterolaemic subjects. Br J Nutr 2013; 109: 1453–1462.

  106. 106.

    , , , . Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice. Int J Obes (Lond) 2013; 37: 279–287.

  107. 107.

    , , , , , et al. Co-administration of SR141716 with peptide YY3-36 or oxyntomodulin has additive effects on food intake in mice. Diabetes Obes Metab 2008; 10: 167–170.

  108. 108.

    . A fatty gut feeling. Trends Endocrinol Metab 2013; 24: 332–341.

  109. 109.

    , , , , , et al. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol 2009; 161: 715–722.

  110. 110.

    , , , , , et al. Biomarkers of endocannabinoid system activation in severe obesity. PLoS One 2010; 5: e8792.

  111. 111.

    , , , , . Central and peripheral endocannabinoids and cognate acylethanolamides in humans: association with race, adiposity, and energy expenditure. J Clin Endocrinol Metab 2011; 96: 115–121.

  112. 112.

    , , , , , . Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 2005; 30: 1216–1221.

  113. 113.

    , , , , , et al. Circulating endocannabinoids and N-acyl-ethanolamides in patients with sleep apnea—specific role of oleoylethanolamide. Exp Clin Endocrinol Diabetes 2010; 118: 591–595.

  114. 114.

    , , , , , et al. Circulating anandamide and blood pressure in patients with obstructive sleep apnea. J Hypertens 2012; 30: 2345–2351.

  115. 115.

    , , , , , et al. Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur Heart J 2011; 32: 1369–1378.

  116. 116.

    , , , , , et al. Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice. Nutr Metab (Lond) 2011; 8: 51.

  117. 117.

    , , , , , et al. Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects. Nutr Metab (Lond) 2011; 8: 7.

  118. 118.

    , , , , . Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry 2013; 18: 1294–1301.

  119. 119.

    , , , , , et al. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol 2010; 161: 629–642.

  120. 120.

    , , , , , et al. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol 2007; 152: 805–814.

Download references

Acknowledgements

This work was supported by INSERM, Aquitaine Region, University of Bordeaux and University Hospital of Bordeaux.

Author information

Affiliations

  1. INSERM, NeuroCentre Magendie, Physiopathologie de la Plasticité Neuronale, U862, Bordeaux, France

    • B Gatta-Cherifi
    •  & D Cota
  2. University of Bordeaux, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U862, Bordeaux, France

    • B Gatta-Cherifi
    •  & D Cota
  3. Department of Endocrinology, Diabetes and Nutrition, University Hospital of Bordeaux, Pessac, France

    • B Gatta-Cherifi

Authors

  1. Search for B Gatta-Cherifi in:

  2. Search for D Cota in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to D Cota.

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/ijo.2015.179

Further reading